



CIVIL ACTION AGAINST MAYNE PHARMA DISCONTINUED IN CANADA

2 September 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX), today announces the Chief Justice of the Federal Court in Canada has issued an Order discontinuing the civil action against Mayne Pharma Inc. and a number of other generic companies. The Order of discontinuance is without costs.

Mayne Pharma Inc was subject to a proposed class action in Canada making allegations of anti-competitive conduct against several generic pharmaceutical companies regarding the sale of generic drugs in Canada. The decision to discontinue the Canadian action against Mayne Pharma Inc. and certain other defendants does not affect ongoing civil complaints made on the same basis in the United States.¹ Mayne Pharma continues to strongly defend the allegations made in these remaining civil complaints.

For further information contact:

Australia:
Dr Tom Duthy
+61 402 493 727
ir@maynepharma.com

US:
Lisa M. Wilson
+1 917-543-9932
ir@maynepharma.com

Authorised for release to the ASX by the Chair

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

¹ Please refer to Mayne Pharma's FY24 Annual Financial Statements, Note 29B (Contingencies) released to ASX 23 August 2024 for further details regarding the US proceedings.